Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» mavacamten
mavacamten
BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision
BioSpace
Mon, 04/4/22 - 10:24 am
Bristol Myers Squibb
FDA
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
ACC 2022 – Bristol's rare hit could justify Myokardia
EP Vantage
Sat, 04/2/22 - 11:38 am
ACC
Bristol Myers Squibb
MyoKardia
hypertrophic cardiomyopathy
mavacamten
BMS builds case for mavacamten label ahead of FDA decision
Pharmaforum
Thu, 02/17/22 - 11:01 am
Bristol Myers Squibb
mavacamten
obtructive hypertrophic cardiomyopathy
MyoKardia
FDA
The biggest launches of 2022: a reboot
EP Vantage
Mon, 02/14/22 - 10:48 am
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Fri, 12/17/21 - 11:18 am
Bristol Myers Squibb
mavacamten
ICER
FDA
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Fri, 11/19/21 - 11:08 am
Bristol Myers Squibb
FDA
ICER
mavacamten
obstructive hypertrophic cardiomyopathy
A couple months ahead of its PDUFA data, Bristol Myers rolls out long-term data for mavacamten
Endpoints
Sat, 11/13/21 - 09:57 pm
Bristol Myers Squibb
FDA
mavacamten
MyoKardia
Bristol Myers backs up its case for heart drug mavacamten as FDA weighs app in cardiomyopathy
Endpoints
Sat, 05/15/21 - 10:58 pm
Bristol Myers Squibb
mavacamten
FDA
cardiac myopathy
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
Xconomy
Mon, 05/11/20 - 11:46 pm
MyoKardia
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
Myokardia at inflection point as heart drug readout nears
BioPharma Dive
Thu, 04/9/20 - 10:40 am
MyoKardia
clinical trials
heart disease
mavacamten
Safety qualms in MyoKardia mid-stage study cause investors to pause
Endpoints
Tue, 11/12/19 - 09:49 am
MyoKardia
obstructive hypertrophic cardiomyopathy
clinical trials
mavacamten
MyoKardia cuts all ties to Sanofi
Biopharma Dive
Thu, 07/18/19 - 05:52 pm
MyoKardia
MYK-224
Sanofi
obstructive hypertrophic cardiomyopathy
mavacamten
MyoKardia raises $251.2M in follow-on
BioCentury
Wed, 03/27/19 - 10:17 am
MyoKardia
mavacamten
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Endpoints
Wed, 01/2/19 - 10:01 am
Sanofi
MyoKardia
mavacamten
obstructive hypertrophic cardiomyopathy
MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring
Xconomy
Mon, 08/7/17 - 10:00 pm
MyoKardia
hypertrophic cardiomyopathy
mavacamten